DE69433844T2 - Lösliche t-zell rezeptoren alpha ketten und derivate verwendet als prophylaktische und therapeutische mittel gegen autoimmune krankheiten - Google Patents

Lösliche t-zell rezeptoren alpha ketten und derivate verwendet als prophylaktische und therapeutische mittel gegen autoimmune krankheiten Download PDF

Info

Publication number
DE69433844T2
DE69433844T2 DE69433844T DE69433844T DE69433844T2 DE 69433844 T2 DE69433844 T2 DE 69433844T2 DE 69433844 T DE69433844 T DE 69433844T DE 69433844 T DE69433844 T DE 69433844T DE 69433844 T2 DE69433844 T2 DE 69433844T2
Authority
DE
Germany
Prior art keywords
soluble
prophylactic
autoimmune diseases
therapeutic agents
cell receptors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69433844T
Other languages
English (en)
Other versions
DE69433844D1 (de
Inventor
Hiroshi Watanabe
Nobuyuki Yamagata
Masaru Taniguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis UK Holdings Ltd
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Publication of DE69433844D1 publication Critical patent/DE69433844D1/de
Application granted granted Critical
Publication of DE69433844T2 publication Critical patent/DE69433844T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
DE69433844T 1993-02-22 1994-02-22 Lösliche t-zell rezeptoren alpha ketten und derivate verwendet als prophylaktische und therapeutische mittel gegen autoimmune krankheiten Expired - Lifetime DE69433844T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP3150193 1993-02-22
JP17906293A JP3875730B2 (ja) 1993-02-22 1993-07-20 自己免疫疾患の予防治療剤
PCT/IB1994/000029 WO1994019470A1 (en) 1993-02-22 1994-02-22 Soluble t-cell receptor alpha chain and derivatives used as prophylactic and therapeutic agents for autoimmune diseases

Publications (2)

Publication Number Publication Date
DE69433844D1 DE69433844D1 (de) 2004-07-22
DE69433844T2 true DE69433844T2 (de) 2005-04-21

Family

ID=26369980

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69433844T Expired - Lifetime DE69433844T2 (de) 1993-02-22 1994-02-22 Lösliche t-zell rezeptoren alpha ketten und derivate verwendet als prophylaktische und therapeutische mittel gegen autoimmune krankheiten

Country Status (12)

Country Link
US (1) US5648332A (de)
EP (1) EP0667908B1 (de)
JP (1) JP3875730B2 (de)
KR (1) KR100333148B1 (de)
AT (1) ATE269409T1 (de)
AU (1) AU686134B2 (de)
CA (1) CA2134083C (de)
DE (1) DE69433844T2 (de)
DK (1) DK0667908T3 (de)
ES (1) ES2224105T3 (de)
PT (1) PT667908E (de)
WO (1) WO1994019470A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08149981A (ja) * 1993-12-13 1996-06-11 La Jolla Inst For Allergy & Immunology T細胞α鎖による抗原特異的免疫制御の方法
WO1997043411A1 (fr) * 1996-05-10 1997-11-20 Kirin Beer Kabushiki Kaisha Peptides a regions constantes de chaine alpha de recepteur des cellules t, leurs procedes de production et leur utilisation
US6162609A (en) * 1997-12-31 2000-12-19 The Brigham And Women's Hospital, Inc. Diagnostic and therapeutic methods based upon Vα24JαQT cells
EP2158923B1 (de) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-uricase Konjugate und Verwendung davon
PL3321359T3 (pl) 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Wariantowe postacie oksydazy moczanowej i ich zastosowanie
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
RU2435847C2 (ru) 2005-04-11 2011-12-10 Савиент Фармасьютикалз, Инк. Вариантная форма урат-оксидазы и ее использование
US9078843B2 (en) 2005-09-22 2015-07-14 Irun R. Cohen Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom
KR101861547B1 (ko) 2009-06-25 2018-07-02 크레알타 파마슈티칼스 엘엘씨 페길화된 유리카아제 치료 중에 혈청 요산을 모니터링하여 주입 반응의 위험성 및 반응의 항체­매개 상실을 예측하는 방법 및 키트

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL86278A (en) * 1988-05-04 2003-06-24 Yeda Res & Dev Endowing cells with antibody specificity using chimeric t cell receptor
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
US6416971B1 (en) * 1990-05-15 2002-07-09 E.R. Squibb & Sons, Inc. Soluble single chain T cell receptors
ES2271940T3 (es) * 1991-02-08 2007-04-16 Aventis Pharma S.A. Secuencias nucleotidicas que codifican regiones variables de cadenas alfa de los receptores de linfocitos humanos asi como sus aplicaciones.
WO1992016234A1 (en) * 1991-03-22 1992-10-01 The Trustees Of The University Of Pennsylvania Method of modulating mammalian t-cell response

Also Published As

Publication number Publication date
AU6042894A (en) 1994-09-14
KR950701387A (ko) 1995-03-23
PT667908E (pt) 2004-09-30
DE69433844D1 (de) 2004-07-22
KR100333148B1 (ko) 2002-12-02
WO1994019470A1 (en) 1994-09-01
ATE269409T1 (de) 2004-07-15
ES2224105T3 (es) 2005-03-01
EP0667908A1 (de) 1995-08-23
JPH06298662A (ja) 1994-10-25
DK0667908T3 (da) 2004-10-11
EP0667908B1 (de) 2004-06-16
CA2134083A1 (en) 1994-09-01
AU686134B2 (en) 1998-02-05
US5648332A (en) 1997-07-15
JP3875730B2 (ja) 2007-01-31
CA2134083C (en) 2000-06-27

Similar Documents

Publication Publication Date Title
GEP20053655B (en) 5-HT Receptor Ligands and Uses Thereof
EA200000299A1 (ru) Лекарства
MA27509A1 (fr) Formulations a liberation prolongee contenant de la lamotrigine
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
RU2008143545A (ru) Применение антагониста рецептора ат-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2
TR199901411T2 (xx) Analjezik etkili yeni bile�imler.
HUP0104696A2 (hu) 5HT1 receptor agonistákat és metoklopramidot tartalmazó gyógyszerkészítmény migrén kezelésére
DE69616480T2 (de) Piperidinderivate als neurokininantagonisten
ATE269409T1 (de) Lösliche t-zell rezeptoren alpha ketten und derivate verwendet als prophylaktische und therapeutische mittel gegen autoimmune krankheiten
BR9808422A (pt) Composto, composição farmacêutica, processos para induzir paralisia neuromuscular em um mamìfero e para a preparação de um composto, e, uso de um composto
BR0010914A (pt) Composto medicamento agente profilático ou terapêutico, e, uso do composto
EP1298203A3 (de) Diagnose und Behandlung von Autoimmunkrankheiten
DE69814049D1 (de) Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
TR199900501T2 (xx) Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�.
DK1189900T3 (da) Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler
HUP9800938A2 (hu) NK-1 receptor antagonisták alkalmazása irritációs bélszindróma tüneteinek kezelésére
HUP0203585A2 (hu) Gyógyszerkombinációk
PE20010541A1 (es) Uso de una composicion de benzimidazol para tratar el cancer
TR199902848T2 (xx) Ergolin t�revleri ve bunlar�n somatostatin resept�r antagonist olarak kullan�mlar�
GB2380939B (en) Treatment or prevention of auto-immune diseases
MX9700959A (es) Derivados de becimidazol que tienen actividad dopaminergica.
ATE275143T1 (de) Verbindungen
BR0105776A (pt) Tratamento de combinação para a depressão,a ansiedade e a psicose
DE69412073T2 (de) Xanthinderivate als adenosin-a1 rezeptor antagonisten
NO963796D0 (no) Retard-tablett inneholdende Diclofenac-Na

Legal Events

Date Code Title Description
8364 No opposition during term of opposition